Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074498 | 0.89 | ALDH1A1 (0.54) | GAAKMT2AMEN1GID4ALDH1A1 | |
| SCHEMBL10382127 | 0.87 | ALDH1A1 (0.53) | GAAKMT2AMEN1GID4HPGD | |
| SCHEMBL9334106 | 0.85 | GAA (0.56) | GAAKMT2AMEN1MCL1HPGD | |
| SCHEMBL23637058 | 0.85 | GAA (0.56) | GAAKMT2AMEN1MCL1HPGD | |
| SCHEMBL13073335 | 0.85 | EPHX1 (0.62) | GAAALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL28044793 | 0.85 | PKM (0.63) | GAAKMT2AMEN1MCL1HPGD | |
| SCHEMBL3689926 | 0.84 | MEP1B (0.68) | GAAKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL25412009 | 0.84 | GAA (0.63) | GAAKMT2AMEN1MCL1HPGD | |
| SCHEMBL10380701 | 0.84 | ALDH1A1 (0.50) | GAAKMT2AMEN1HPGDALDH1A1 | |
| SCHEMBL7747993 | 0.84 | ALDH1A1 (0.50) | GAAKMT2AMEN1GID4MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698170-A1 | GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS | Eberhard-Karls-Universität Tübingen (DE) | 2026-02-25 | — | — | EP | disclosed |
| WO-2024218333-A1 | GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS | EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT (DE) | 2024-10-24 | — | — | WO | disclosed |
| US-20110319636-A1 | METHOD FOR PREPARATION OF AMIDES FROM ALCOHOLS AND AMINES BY EXTRUSION OF HYDROGEN | TECHNICAL UNIVERSITY OF DENMARK | 2011-12-29 | — | — | US | disclosed |
| EP-1155327-A1 | BIOLOGICAL SAMPLE COMPONENT PURIFICATION AND DIFFERENTIAL DISPLAY | CHIRON CORPORATION (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2001033230-A2 | BIOLOGICAL SAMPLE COMPONENT PURIFICATION AND DIFFERENTIAL DISPLAY | CHIRON CORPORATION (US) | 2001-05-10 | — | — | WO | disclosed |
| US-6017660-A | PIGMENTED INK COMPRISING ADDITION POLYMER MONOMER, PHOTOINITATOR MIXTURE CONTAINING A DIARYLIODONIUM SALT, SENSITIZER FOR 2-METHYL-4,6-BIS(TRICHLOROMETHYL)-S-TRIAZINE, AND ELECTRON DONOR COMPOUND; PHOTOCURABLE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0216746-B1 | PROCESS TO PREPARE 2,5-DIKETOPIPERAZINES | Monsanto Company (US) | 1990-10-24 | — | — | EP | disclosed |
| US-4694081-A | FUNGICIDES | MONSANTO COMPANY (US) | 1987-09-15 | — | — | US | disclosed |
| EP-0216746-A2 | Process to prepare 2,5-diketopiperazines | Monsanto Company (US) | 1987-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319636-A1 | METHOD FOR PREPARATION OF AMIDES FROM ALCOHOLS AND AMINES BY EXTRUSION OF HYDROGEN | ADH1C, ADH5, ADH1A | GAA 3883/4885KMT2A 1117/4885MEN1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.